Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology.
According to Aspire, the technology is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients (APIs) and other substances into the bloodstream, increasing bioavailability and improving speed of onset.
In a statement, Kraig Higginson, interim CEO of Aspire, commented, “The filing of this omnibus patent application for our sublingual delivery platform marks another important step in strengthening our intellectual property portfolio among many classes of drugs. We believe our technology has the potential to transform sublingual drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes.”
